MGC Pharma submits patent application for virus symptoms treatment

MGC Pharmaceuticals Ltd (LON:MXC) (ASX:MXC) said it has submitted a patent application for its CimetrA medical product to the Slovenian Intellectual Property Office (SIPO). CimetrA is designed to treat multiple ailments including viral infections with acute and chronic inflammation, COVID-19 and variants of influenza, autoimmune diseases, adverse events resulting from the various forms of cancer therapy, and the promotion of an immune response to bacterial, viral, fungal and parasitic infections. READ: MGC Pharmaceuticals shares boosted by latest ArtemiC results in COVID-19 study The developer of phytocannabinoid-derived medicines said the patent application was accepted by SIPO on May 5 and gives the company priority to file subsequent patent applications for CimetrA in other jurisdictions and other IP agencies such as EU and the World Intellectual Property Organisation (WIPO). The firm added that it expects the patent to be issued within the next 12 months, meanwhile, it said is continuing to progress towards the commencement of its phase III clinical trial for CimetrA to demonstrate the full efficacy and pharmacokinetic profile of the treatment in different variants of the COVID-19 virus. “We are delighted that the SIPO recognises the unique formulation of CimetrA, something we believe will be transformational in the treatment of COVID-19 as well as numerous other conditions. The submission of this patent application is an important next step in bringing CimetrA to market in multiple jurisdictions and ultimately treating people and patients on a global scale whilst Phase III trials for the IMP continue,” MGC co-founder and managing director Roby Zomer said in a statement. Shares in MGC were 3.2% lower at 3p in early deals on Monday.